Medical and Surgical Evaluation and Treatment of Adrenal Incidentalomas
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Adrenal incidentalomas are detected in approximately 4% of patients undergoing high-resolution abdominal imaging studies. The majority of adrenal incidentalomas are benign, but careful evaluation of all patients is warranted to be certain that primary adrenocortical carcinoma and functional adenomas are not missed. METHODS: The diagnostic approach in patients with adrenal incidentalomas should focus on two main questions: whether the lesion is malignant, and whether it is hormonally active. Radiological evaluation including noncontrast and contrast computed tomography attenuation values expressed in Hounsfield units is the best tool to differentiate between benign and malignant adrenal masses. All adrenal tumors with suspicious radiological findings, most functional tumors, and all tumors more than 4 cm in size that lack characteristic benign imaging features should be surgically excised. All patients should undergo hormonal evaluation for subclinical Cushing's syndrome and pheochromocytoma, and those with hypertension should also be evaluated for hyperaldosteronism. Combined 1-mg dexamethasone suppression test, plasma metanephrines, and aldosterone/plasma renin activity measurements (if hypertensive) are reasonable initial hormonal evaluations. RESULTS: Annual biochemical follow-up of most patients with adrenal incidentalomas, especially if the tumor is more than 3 cm in size, for up to 5 yr may be reasonable. Patients with adrenal masses less than 4 cm in size and a noncontrast attenuation value of more than 10 Hounsfield units should have a repeat computed tomography study in 3-6 months and then yearly for 2 yr. Adrenal tumors with indeterminate radiological features that grow to at least 0.8 cm over 3-12 months may be considered for surgical resection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 1×
“Despite the lack of a single “gold standard” test to diagnose SCS, the authors consider a combination of the 1-mg DST and plasma ACTH level as the best diagnostic tool for evaluation of patients suspected to have SCS (20, 21, 48).”
BackgroundFunder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554
Biochemical Diagnosis of Pheochromocytoma: Which Test Is Best?
Lenders, J. W. M., Pacak, K., Walther, M. M., Linehan, W. M., Mannelli, M., Friberg, P., Keiser, H. R., Goldstein, D. S., & Eisenhofer, G. (2002) · JAMA · doi:10.1001/jama.287.11.1427 · Cited by 1,134
Management of the clinically inapparent adrenal mass ("incidentaloma")
Grumbach, M. M., Biller, B. M. K., Braunstein, G. D., Campbell, K. K., Carney, J. A., Godley, P. A., Harris, E. L., Lee, J. K. T., Oertel, Y. C., Posner, M. C., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-5-200303040-00013 · Cited by 945 · cited 5×
“The National Institutes of Health consensus statement included recommendations for limited follow-up only for nonfunctional adenomas of less than 3 cm with no specific recommendations (20).”
BackgroundMethodInfluentialThe clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781 · cited 2×
“ports summarizing the result of 25 autopsy studies is about 6% (1, 3, 4).”
BackgroundPrevalence of adrenal incidentaloma in a contemporary computerized tomography series
Bovio, S., Cataldi, A., Reimondo, G., Sperone, P., Novello, S., Berruti, A., Borasio, P., Fava, C., Dogliotti, L., Scagliotti, G. V., et al. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344099 · Cited by 712
Primary aldosteronism: renaissance of a syndrome
Young, W. F. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02775.x · Cited by 680
Sawka, A. M., Jaeschke, R., Singh, R. J., & Young, W. F. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021251 · Cited by 503
Zeiger, M. A., Thompson, G. B., Duh, Q.-Y., Hamrahian, A. H., Angelos, P., Elaraj, D., Fishman, E., Kharlip, J., Zeiger, M. A., Thompson, G. B., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.s1.1 · Cited by 499
Self-citationRenal Damage in Primary Aldosteronism: Results of the PAPY Study
Rossi, G. P., Bernini, G., Desideri, G., Fabris, B., Ferri, C., Giacchetti, G., Letizia, C., Maccario, M., Mannelli, M., Matterello, M.-J., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000230444.01215.6a · Cited by 470
MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS
Young, W. F. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70122-5 · Cited by 415
Tauchmanovà, L., Rossi, R., Biondi, B., Pulcrano, M., Nuzzo, V., Palmieri, E.-A., Fazio, S., & Lombardi, G. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-011766 · Cited by 400
CT time-attenuation washout curves of adrenal adenomas and nonadenomas
Korobkin, M., Brodeur, F. J., Francis, I. R., Quint, L. E., Dunnick, N. R., & Londy, F. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.170.3.9490968 · Cited by 386
Adrenal incidentaloma: a new cause of the metabolic syndrome?
Terzolo, M., Pia, A., Alì, A., Osella, G., Reimondo, G., Bovio, S., Daffara, F., Procopio, M., Paccotti, P., Borretta, G., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8277 · Cited by 322
Delayed enhanced CT of lipid-poor adrenal adenomas
Caoili, E. M., Korobkin, M., Francis, I. R., Cohan, R. H., & Dunnick, N. R. (2000) · American Journal of Roentgenology · doi:10.2214/ajr.175.5.1751411 · Cited by 305
Cawood, T. J., Hunt, P. J., O'Shea, D., Cole, D., & Soule, S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0234 · Cited by 300 · cited 6×
“1–11% for pheochromocytomas in patients with adrenal incidentalomas has been reported, but it is probably closer to 3% (2, 7, 75, 76).”
BackgroundResultInfluentialSubclinical Cushing’s syndrome
Reincke, M. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70115-8 · Cited by 285
Angeli, A., Osella, G., Ali, A., & Terzolo, M. (1997) · Hormone Research · doi:10.1159/000185477 · Cited by 259 · cited 1×
“Adrenal incidentalomas are bilateral in less than 15% of cases (60, 122).”
BackgroundToniato, A., Merante-Boschin, I., Opocher, G., Pelizzo, M. R., Schiavi, F., & Ballotta, E. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e31819a47d2 · Cited by 245
Long-term follow-up study of patients with adrenal incidentalomas.
Libe, R., Dall'Asta, C., Barbetta, L., Baccarelli, A., Beck-Peccoz, P., & Ambrosi, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470489 · Cited by 215 · cited 2×
“Until data from large prospective studies are available, annual biochemical follow-up for up to 5 yr may be reasonable for patients with adrenal incidentalomas, especially if the tumor is more than 3 cm in size (20, 21, 37, 45).”
BackgroundMethodSubclinical Cushing's syndrome in adrenal incidentaloma.
Terzolo, Osella, Alì, Borretta, Cesario, Paccotti, & Angeli, A. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00357.x · Cited by 198
Sturgeon, C., Shen, W. T., Clark, O. H., Duh, Q.-Y., & Kebebew, E. (2006) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2005.11.005 · Cited by 194
Chiodini, I., Morelli, V., Salcuni, A. S., Eller-Vainicher, C., Torlontano, M., Coletti, F., Iorio, L., Cuttitta, A., Ambrosio, A., Vicentini, L., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2387 · Cited by 191
Development of overt Cushing’s syndrome in patients with adrenal incidentaloma
Barzon, L., Fallo, F., Sonino, N., & Boscaro, M. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460061 · Cited by 162 · cited 1×
“Adrenal incidentalomas are bilateral in less than 15% of cases (60, 122).”
BackgroundA survey on incidental adrenal tumors in Japan
Aso, Y., & Homma, Y. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37601-2 · Cited by 136
Subclinical hormone secretion by incidentally discovered adrenal masses
Caplan, R. H. (1994) · Archives of Surgery · doi:10.1001/archsurg.1994.01420270067016 · Cited by 133
Nunes, M.-L., Vattaut, S., Corcuff, J.-B., Rault, A., Loiseau, H., Gatta, B., Valli, N., Letenneur, L., & Tabarin, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1542 · Cited by 129
Adrenal incidentaloma—follow-up results from a Swedish prospective study.
Bülow, B., Jansson, S., Juhlin, C., Steen, L., Thorén, M., Wahrenberg, H., Valdemarsson, S., Wängberg, B., Ahréen, B., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02110 · Cited by 124 · cited 1×
“Excess hormone secretion may develop in up to 20% of patients with previously nonfunctional adrenal tumors during follow-up (37, 38, 123).”
BackgroundBülow, B., Ahrén, B., & the Swedish Research Council Study Group of Endocrine Abdominal Tumours (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01028.x · Cited by 120 · cited 1×
“1–11% for pheochromocytomas in patients with adrenal incidentalomas has been reported, but it is probably closer to 3% (2, 7, 75, 76).”
BackgroundHormonal activity of adrenal incidentalomas: results from a long-term follow-up study
Vassilatou, E., Vryonidou, A., Michalopoulou, S., Manolis, J., Caratzas, J., Phenekos, C., & Tzavara, I. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03492.x · Cited by 112
Morelli, V., Masserini, B., Salcuni, A. S., Eller‐Vainicher, C., Savoca, C., Viti, R., Coletti, F., Guglielmi, G., Battista, C., Iorio, L., et al. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03794.x · Cited by 107
“Subclinical Cushing’s syndrome” is not subclinical: improvement after adrenalectomy in 9 patients
Mitchell, I. C., Auchus, R. J., Juneja, K., Chang, A. Y., Holt, S. A., Snyder, W. H., & Nwariaku, F. E. (2007) · Surgery · doi:10.1016/j.surg.2007.10.001 · Cited by 84
MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS
Mantero, F., & Arnaldi, G. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70119-5 · Cited by 83
Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas.
Valli, N., Catargi, B., Ronci, N., Vergnot, V, Leccia, F., Ferriere, J., Chene, G., Grenier, N., Laurent, F., & Tabarin, A. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440401 · Cited by 83
Chiodini, I., Guglielmi, G., Battista, C., Carnevale, V., Torlontano, M., Cammisa, M., Trischitta, V., & Scillitani, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031413 · Cited by 82
Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism
Tauchmanovà, L., Pivonello, R., De Martino, M. C., Rusciano, A., De Leo, M., Ruosi, C., Mainolfi, C., Lombardi, G., Salvatore, M., & Colao, A. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0137 · Cited by 80
Eller-Vainicher, C., Morelli, V., Salcuni, A. S., Torlontano, M., Coletti, F., Iorio, L., Cuttitta, A., Ambrosio, A., Vicentini, L., Carnevale, V., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0775 · Cited by 75
Eller-Vainicher, C., Morelli, V., Salcuni, A. S., Battista, C., Torlontano, M., Coletti, F., Iorio, L., Cairoli, E., Beck-Peccoz, P., Arosio, M., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0602 · Cited by 73 · cited 1×
“Others have advocated different test combinations, including 1-mg DST, 24-h urinary free cortisol, and plasma ACTH level (49, 50).”
BackgroundMarko, N. F., Gonugunta, V. A., Hamrahian, A. H., Usmani, A., Mayberg, M. R., & Weil, R. J. (2009) · Journal of Neurosurgery · doi:10.3171/2008.12.jns081265 · Cited by 67
Self-citationIncidentally Discovered Adrenal Tumors: A Lesson from Observation of 1444 Patients
Kasperlik-Załuska, A., Otto, M., Cichocki, A., Rosłonowska, E., Słowińska-Srzednicka, J., Jeske, W., Papierska, L., & Zgliczyński, W. (2008) · Hormone and Metabolic Research · doi:10.1055/s-2008-1073167 · Cited by 56 · cited 1×
“1–11% for pheochromocytomas in patients with adrenal incidentalomas has been reported, but it is probably closer to 3% (2, 7, 75, 76).”
BackgroundBarzon, L., Fallo, F., Sonino, N., & Boscaro, M. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450223 · Cited by 21
Donadio, F., Morelli, V., Salcuni, A. S., Eller-Vainicher, C., Carletto, M., Castellani, M., Dellavedova, L., Scillitani, A., Beck-Peccoz, P., & Chiodini, I. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03346511 · Cited by 13
Cited by
Berends, A. M. A., Buitenwerf, E., de Krijger, R. R., Veeger, N. J. G. M., van der Horst-Schrivers, A. N. A., Links, T. P., & Kerstens, M. N. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.015 · Cited by 257
Clinical guidelines for the management of adrenal incidentaloma
Lee, J.-M., Kim, M. K., Ko, S.-H., Koh, J.-M., Kim, B.-Y., Kim, S. W., Kim, S.-K., Kim, H. J., Ryu, O.-H., Park, J., et al. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.2.200 · Cited by 147
CT characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma
Canu, L., Van Hemert, J. A. W., Kerstens, M. N., Hartman, R. P., Khanna, A., Kraljevic, I., Kastelan, D., Badiu, C., Ambroziak, U., Tabarin, A., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01532 · Cited by 131
Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study
Buitenwerf, E., Korteweg, T., Visser, A., Haag, C. M. S. C., Feelders, R. A., Timmers, H. J. L. M., Canu, L., Haak, H. R., Bisschop, P. H. L. T., Eekhoff, E. M. W., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0006 · Cited by 72
Vassilatou (2014) · doi:10.1530/eje-13-0848 · Cited by 61
Metadata
- Authors
- Zeiger, M. A., Siegelman, S. S., & Hamrahian, A. H.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-07
- Volume
- 96
- Issue
- 7
- Pages
- 2004-2015
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2117342292
- Cited by
- 135
- References
- 42
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.